effectiveness of tofacitinib in moderate to severe ulcerative colitis compared to steroid
Phase 4
Completed
- Conditions
- Health Condition 1: K519- Ulcerative colitis, unspecified
- Registration Number
- CTRI/2023/09/057448
- Lead Sponsor
- Shankar Roy
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 94
Inclusion Criteria
diagnosed cases of ulcerative colitis
Exclusion Criteria
ulcerative proctitis, severe commorbidity, c. difficile infection, toxic mega colon, any coagulopathy or hypercoaguable condition, thrombosis, pregnancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method to compare the remission rate in both steroid and tofacitinib groupTimepoint: at 4th week, 8th week and 12th week
- Secondary Outcome Measures
Name Time Method to compare the safety profile and adverse events of the individual drugsTimepoint: 3 months